Literature DB >> 20971677

Ocular surface disease: a case of vernal keratoconjunctivitis.

DeGaulle I Chigbu1, Shanthy Sandrasekaramudaly-Brown.   

Abstract

Vernal keratoconjunctivitis (VKC) is a recurrent, chronic allergic inflammation of the ocular surface associated with remodeling of the cornea and conjunctiva, with a potential to adversely affect the patient's vision and quality of life. It affects mainly children and young adults. The purpose of this interventional case report is to present a typical case of limbal VKC, which was unresponsive to antiallergic treatment alone. A 5-year-old boy, who was previously unsuccessful with conventional anti-allergic therapy alone, presented with clinicopathological features pathognomonic of limbal VKC. The patient was successfully managed with a combination of palliative, anti-allergic and anti-inflammatory therapy. Prophylaxis with an anti-allergic pharmaceutical agent was initiated for long term use to prevent the release of allergic mediators. This case highlights the importance of prescribing the most appropriate pharmaceutical medication for VKC since conjunctival fibroproliferative lesions are often resistant to anti-allergy therapy. Allergic inflammatory mediators are responsible for the fibroproliferative changes of the conjunctiva and corneal lesions in VKC. Thus, it is crucial to prescribe the most appropriate pharmaceutical medication that will prevent the release of allergic inflammatory mediators, control the allergic inflammatory cascade and prevent ocular surface damage. The fine points of this case are presented with a review of applicable literature.
Copyright © 2010 British Contact Lens Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20971677     DOI: 10.1016/j.clae.2010.09.002

Source DB:  PubMed          Journal:  Cont Lens Anterior Eye        ISSN: 1367-0484            Impact factor:   3.077


  2 in total

1.  Corneal biochemical features of patients with vernal keratoconjunctivitis.

Authors:  Sinan Emre; Esin Başer; Bilge Oztürk; Sibel Zorlu; Ozgür Uzun; Ceren Gülhan
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-06-22       Impact factor: 3.117

Review 2.  Update and clinical utility of alcaftadine ophthalmic solution 0.25% in the treatment of allergic conjunctivitis.

Authors:  DeGaulle I Chigbu; Alissa M Coyne
Journal:  Clin Ophthalmol       Date:  2015-07-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.